Edwin DeJesus

19.2k total citations · 5 hit papers
149 papers, 9.8k citations indexed

About

Edwin DeJesus is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Edwin DeJesus has authored 149 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Infectious Diseases, 119 papers in Virology and 39 papers in Emergency Medicine. Recurrent topics in Edwin DeJesus's work include HIV/AIDS drug development and treatment (134 papers), HIV Research and Treatment (119 papers) and HIV/AIDS Research and Interventions (68 papers). Edwin DeJesus is often cited by papers focused on HIV/AIDS drug development and treatment (134 papers), HIV Research and Treatment (119 papers) and HIV/AIDS Research and Interventions (68 papers). Edwin DeJesus collaborates with scholars based in United States, United Kingdom and Germany. Edwin DeJesus's co-authors include Andrew Cheng, Joel E. Gallant, Anton Pozniak, Damian J. McColl, Jeffrey Enejosa, José Ramón Arribas, Adriano Lazzarin, Peter Ruane, John J. Toole and Kirsten White and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Edwin DeJesus

147 papers receiving 9.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. New England Journal of Medicine profile →
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

2009 478 citations Jeffrey L. Lennox, Edwin DeJesus et al. The Lancet profile →
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Edwin DeJesus, Peter Ruane et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Edwin DeJesus

Since Specialization

Citations

This map shows the geographic impact of Edwin DeJesus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin DeJesus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin DeJesus more than expected).

Fields of papers citing papers by Edwin DeJesus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin DeJesus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin DeJesus. The network helps show where Edwin DeJesus may publish in the future.

Co-authorship network of co-authors of Edwin DeJesus

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin DeJesus. A scholar is included among the top collaborators of Edwin DeJesus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin DeJesus. Edwin DeJesus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod 2024 ·Infectious Diseases and Therapy ·Sharon A. Riddler, Constance A. Benson, (unknown), Steven G. Deeks, Edwin DeJesus, (unknown), Michael F. Para, Moti Ramgopal, Yanhui Cai, (unknown), (unknown), Wendy Jiang, Xiaopeng Liu, (unknown), (unknown), Christiaan R. de Vries, Jeffrey J. Wallin, Elena Vendrame, Devi SenGupta	1
2	1603. Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study 2023 ·Open Forum Infectious Diseases ·Charlotte-Paige Rolle, (unknown), Vu Cong Nguyen, Federico Hinestrosa, Edwin DeJesus	1
3	Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection 2020 ·Journal of the International AIDS Society ·Edwin DeJesus, Jean‐Michel Molina, Yazdan Yazdanpanah, (unknown), Christopher Bettacchi, (unknown), Stephanie O. Klopfer, Anjana Grandhi, Karen Eves, Michael Robertson, Peter Sklar, Carey Hwang, George J. Hanna, (unknown)	2
4	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
5	P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate 2015 ·Journal of the International AIDS Society ·Edwin DeJesus, (unknown), Michael T. Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoît Trottier, Jaime Andrade‐Villanueva, Huyen Cao, (unknown), Marshall W. Fordyce	9
6	P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy 2015 ·Journal of the International AIDS Society ·Edwin DeJesus, (unknown), Anton Pozniak, Melanie Thompson, Daniel Podzamczer, Jean‐Michel Molina, Gordon Crofoot, Christian Callebaut, Hal Martin, (unknown), Scott McCallister	9
7	P24: Long-term efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir plus ritonavir plus emtricitabine/tenofovir 2014 ·Journal of the International AIDS Society ·(unknown), (unknown), (unknown), (unknown), (unknown), Edwin DeJesus, Xuelian Wei, (unknown), (unknown), (unknown), (unknown)	1
8	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results 2013 ·The Journal of Infectious Diseases ·Joel E. Gallant, Ellen Koenig, Jaime Andrade‐Villanueva, Ploenchan Chetchotisakd, Edwin DeJesus, Francisco Antunes, Keikawus Arastéh, Graeme Moyle, Giuliano Rizzardini, Jan Fehr, Yapei Liu, Lijie Zhong, Christian Callebaut, Javier Szwarcberg, Martin S. Rhee, Andrew Cheng	84
9	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	335
10	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger, Adriano Lazzarin, Richard B. Pollard, José Valdez Madruga, Jing Zhao, Hong Wan, Christopher L. Gilbert, Hedy Teppler, Anthony Rodgers, Richard J. O. Barnard, Michael D. Miller, Mark J. DiNubile, Bach-Yen Nguyen, Randi Y. Leavitt, Peter Sklar	194
11	Patient-Reported Outcomes in Virologically Suppressed, HIV-1–Infected Subjects After Switching to a Simplified, Single-Tablet Regimen of Efavirenz, Emtricitabine, and Tenofovir DF 2010 ·AIDS Patient Care and STDs ·Sally Hodder, Karam Mounzer, Edwin DeJesus, Ramin Ebrahimi, (unknown), (unknown), (unknown), Awny Farajallah, John F. Flaherty	67
12	Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758 2009 ·AIDS Research and Human Retroviruses ·Charles B. Hicks, Edwin DeJesus, Louis Sloan, Michael Sension, David A. Wohl, Qiming Liao, Lisa Ross, Gary E. Pakes, Keith A. Pappa, (unknown)	17
13	Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263) 2009 ·AIDS Research and Human Retroviruses ·Lisa Ross, Richard Elion, Randall Lanier, Edwin DeJesus, Calvin Cohen, Robert Redfield, Joseph Gathe, (unknown), Linda Yau, (unknown), Belinda Ha	9
14	Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily Efavirenz-Based Regimen in Treatment-Naïve HIV-1–Infected Patients Over 96 Weeks 2009 ·HIV Clinical Trials ·Dushyantha Jayaweera, Edwin DeJesus, Kim L. Nguyen, (unknown), D. Butcher, Daniel Seekins	18
15	Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults 2008 ·Antimicrobial Agents and Chemotherapy ·Jeffrey M. Jacobson, Daniel R. Kuritzkes, Eliot Godofsky, Edwin DeJesus, Jeffrey A. Larson, Steven P. Weinheimer, Stanley T. Lewis	125
16	Elvucitabine Phase II 48 Week Interim Results Show Safety and Efficacy Profiles Similar to Lamivudine in Treatment Naive HIV-1 Infected Patients with a Unique Pharmacokinetic Profile 2008 ·46th Annual Meeting ·Edwin DeJesus	3
17	96-Week Efficacy/Safety Data Comparing Two Doses of Ritonavir (/r) to Boost Once-Daily (QD) Fosamprenavir (FPV), Used in Combination with Abacavir (ABC)/Lamivudine (3TC) 2008 ·46th Annual Meeting ·Edwin DeJesus	3
18	Adherence to Enfuvirtide and Its Impact on Treatment Efficacy 2008 ·AIDS Research and Human Retroviruses ·Jürgen K. Rockstroh, Edwin DeJesus, (unknown), Cynthia Wat, A Bertasso, Emily Labriola–Tompkins, (unknown), (unknown), (unknown), Timothy D. Wilkinson, James Thommes, Lucy Rowell, Ralph DeMasi, Miklos Salgo	4
19	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, (unknown), (unknown), John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer	570
20	Advances in HIV therapeutics: news from the 4th International AIDS Society Conference. 2007 ·PubMed ·(unknown), Richard Elion, Calvin Cohen, Edwin DeJesus, Trevor Hawkins, Graeme Moyle	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact